Clinical trials are becoming increasingly expensive, and patients are more and more reluctant to enroll and to persist with the protocol, further increasing costs. We propose to develop Bayesian statistical methods and software for more efficient, ethical, and affordable clinical trials. These methods incorporate all sources of knowledge (structural constraints, expert opinion, and both historical and experimental data), thus reducing sample size and typically leading to increases in statistical power and reductions in cost and ethical hazard, since fewer patients need be exposed to the inferior treatment. The methods are also better able to adapt to unanticipated changes that inevitably arise as the trial progresses.
In Aim 1 we will develop novel methods to exploit available historical data.
In Aim 2 we look at the more general problem of combining inference across related subpopulations, when the subpopulations are not exchangeable. Here our approach is based on random clustering of subpopulations. Finally, Aim 3 is concerned with the development of user-friendly computer code that can be publicly distributed. The end result will be clinical trials that come to conclusions more quickly with fewer patients randomized to inferior treatments. Our methods and software should have immediate impact on practice not only for early phase studies, but for large confirmatory trials as well. In the longer term, improvements in trial compliance and accrual should also obtain.
of this work to public health lies in its ability to randomize fewer patients to control groups in clinical trials, since reliable historical information on such groups will be brought to bear. Patients are thus treated more ethically, and trial conclusions are obtained more quickly. The work has a potentially large impact on small studies of interventions in cancer, alcohol, and many other areas where sample sizes are small yet other sources of information exist that can accelerate the process while maintaining scientific integrity.
|Thall, Peter F; Mueller, Peter; Xu, Yanxun et al. (2017) Bayesian nonparametric statistics: A new toolkit for discovery in cancer research. Pharm Stat 16:414-423|
|Xu, Yanxun; Trippa, Lorenzo; Müller, Peter et al. (2016) Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials. Stat Biosci 8:159-180|
|Schnell, Patrick M; Tang, Qi; Offen, Walter W et al. (2016) A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects. Biometrics 72:1026-1036|
|Zhao, Hong; Hobbs, Brian P; Ma, Haijun et al. (2016) Combining Non-randomized and Randomized Data in Clinical Trials Using Commensurate Priors. Health Serv Outcomes Res Methodol 16:154-171|
|Murray, Thomas A; Hobbs, Brian P; Sargent, Daniel J et al. (2016) Flexible Bayesian survival modeling with semiparametric time-dependent and shape-restricted covariate effects. Bayesian Anal 11:381-402|
|Lee, Juhee; Thall, Peter F; Ji, Yuan et al. (2016) A decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics 17:304-19|
|Xu, Yanxun; Müller, Peter; Wahed, Abdus S et al. (2016) Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times. J Am Stat Assoc 111:921-935|
|Hong, Hwanhee; Chu, Haitao; Zhang, Jing et al. (2016) A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons. Res Synth Methods 7:6-22|
|Cunanan, Kristen M; Carlin, Bradley P; Peterson, Kevin A (2016) A practical Bayesian stepped wedge design for community-based cluster-randomized clinical trials: The British Columbia Telehealth Trial. Clin Trials 13:641-650|
|Koopmeiners, Joseph S; Hobbs, Brian P (2016) Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials. Stat Methods Med Res :|
Showing the most recent 10 out of 26 publications